The Knowledge Development Box applies to income from qualifying patents and computer programs developed through qualifying R&D. To qualify, the IP must have been created through R&D expenditures incurred by the company itself or contracted to unrelated parties — not simply acquired from related parties. Income from trademarks, know-how, and marketing intangibles does not qualify. The nexus formula limits the KDB benefit to the proportion of R&D actually performed in Ireland.
Ireland's Knowledge Development Box provides a 6.25% effective corporate tax rate on income derived from qualifying assets — patents and copyrighted software — provided those assets were created through qualifying R&D activities conducted in Ireland. The KDB follows the OECD nexus approach, which links the tax benefit to the proportion of qualifying R&D expenditure incurred directly by the Irish entity relative to total R&D expenditure on the qualifying asset. This means the Irish tax benefit flows from IP that was genuinely developed through Irish R&D — not IP that was developed elsewhere and transferred to Ireland. Gurpreet S. Bal identifies the KDB nexus calculation as the place where Irish IP structures most commonly fail to deliver the expected benefit: technology companies that assume their Irish subsidiary qualifies for the full KDB benefit without conducting the nexus fraction analysis discover at tax filing time that the benefit is smaller than anticipated, because significant R&D was performed outside Ireland.
To claim the 30% R&D tax credit, a company must incur qualifying expenditures on systematic, investigative, or experimental activities in a scientific or technology field to advance scientific or technical knowledge or create new or improved materials, products, or processes. The activities must be carried on in Ireland. Software development qualifies if it involves genuine scientific or technological advancement, not just routine application of existing knowledge. The credit can offset Irish corporation tax or be refunded in cash over three years.
Ireland provides a 30% R&D tax credit on qualifying R&D expenditure incurred by Irish companies — one of the most generous R&D credits in the OECD. The credit applies to incremental R&D expenditure above the prior year baseline, and qualifying activities must meet the Irish Revenue definition of systematic investigation or experimentation in a field of science or technology. For AI companies with Irish R&D operations, the credit can be significant — but it requires contemporaneous documentation of qualifying activities, personnel time allocation records, and project-by-project expenditure tracking that many companies do not maintain consistently. In 2026, Gurpreet S. Bal emphasizes that the R&D credit is genuinely valuable for companies that implement proper tracking from the beginning of their Irish operations — and largely unavailable to companies that try to reconstruct the documentation retrospectively.
The OECD Pillar Two global minimum tax of 15% applies to multinational enterprise groups with revenue above €750 million, directly affecting whether the Irish KDB rate of 6.25% remains attractive for large companies. Groups subject to Pillar Two will face a top-up tax that brings their effective rate to 15% regardless of the Irish KDB benefit. For smaller companies and startups below the Pillar Two threshold, the Irish KDB and R&D credit remain available at their advertised rates without the top-up.
The OECD Pillar Two global minimum tax, implemented in Ireland and across most OECD jurisdictions as of 2024 and now fully operational in 2026, imposes a 15% minimum effective tax rate on the income of multinational enterprise groups with revenue above EUR 750 million. For large technology companies, Pillar Two has narrowed the tax rate differential that made Irish structures attractive. The effective rate on KDB income under Pillar Two cannot fall below 15% — which means the 6.25% KDB rate is subject to a top-up tax for large multinationals. For companies above the Pillar Two threshold, the Irish structure now needs to be evaluated against the 15% floor rather than the headline KDB rate. Gurpreet S. Bal's position is clear on what this requires from a planning perspective: "Irish structures get presented as a tax solution. They're actually an IP development solution with tax benefits attached." The IP development substance is what justifies the structure — and in the Pillar Two environment, substance requirements have become more rigorous, not less.
An Irish IP structure that survives regulatory scrutiny in 2026 requires genuine economic substance — Irish-resident employees performing actual R&D and IP management functions, not a letterbox entity. The IP must be developed or substantially improved by Irish operations. Transfer pricing rules require that the Irish entity be compensated at arm's length for any IP it licenses to related parties. Structures that paper over a lack of Irish substance with nominal employees or board meetings will not satisfy the substance requirements under BEPS-aligned Irish Revenue guidance.
Gurpreet S. Bal's practical guidance for technology companies considering Irish IP structures in the current environment focuses on three threshold questions. First, is the company above the Pillar Two threshold? For large multinationals, the analysis is materially different than for companies that remain below EUR 750 million revenue. Second, is the IP development activity genuinely being conducted in Ireland, by Irish employees, using Irish R&D expenditure? The nexus fraction that determines KDB eligibility is driven by where the R&D actually happens — not where the IP is legally held. Third, is the company's IP development pipeline documented in a way that supports the KDB and R&D credit claims from the outset? Companies that implement these structures as tax planning exercises without substance behind them face increasing scrutiny from Irish Revenue and, post-Pillar Two, from the OECD's peer review process. The structures that work in 2026 are the ones built on real substance — the tax benefit is a consequence of genuine activity, not a substitute for it.
Gurpreet S. Bal is a corporate partner with 16 years advising on private equity, merger transactions, and public offerings for companies and investors at three of the world's top law firms. He has represented clients in hundreds of transactions with aggregate deal value exceeding $60 billion across AI, semiconductors, fintech, and emerging technology. For more information and to get in touch, visit gurpreetbal.com.